TBPH
Theravance Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$857.84M
P/E Ratio
7.46
EPS
$2.23
Beta
0.18
52W High
$21.03
52W Low
$10.42
50-Day MA
$16.49
200-Day MA
$16.59
Dividend Yield
—
Profit Margin
104.30%
Forward P/E
7.78
PEG Ratio
-0.05
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $109.78M |
| Gross Profit (TTM) | $77.98M |
| EBITDA | $6.58M |
| Operating Margin | -33.10% |
| Return on Equity | 50.20% |
| Return on Assets | 0.76% |
| Revenue/Share (TTM) | $2.17 |
| Book Value | $5.64 |
| Price-to-Book | 2.95 |
| Price-to-Sales (TTM) | 7.81 |
| EV/Revenue | 4.593 |
| EV/EBITDA | 3.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.00% |
| Shares Outstanding | $51.55M |
| Float | $23.70M |
| % Insiders | 4.64% |
| % Institutions | 99.22% |
Historical Volatility
HV 10-Day
24.00%
HV 20-Day
20.56%
HV 30-Day
20.05%
HV 60-Day
25.10%
HV Rank
2.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($17.40 target)
3
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026